Cargo Therapeutics files for IPO, aiming to raise money to fund cell therapy ambitions

A cancer cell therapy biotech that emerged just nine months ago with $200 million and a Phase I trial already underway will test the public markets just weeks ahead of an expected holiday pause on initial public offerings.

Cargo Therapeutics, born out of the work of Stanford CAR-T leader Click here to view original post